Navigation Links
Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Sinemet(R)
Date:9/30/2009

PITTSBURGH, Sept. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.

Carbidopa and Levodopa Tablets are the generic version of Bristol Myers Squibb's Parkinson's treatment Sinemet®, 10mg/100mg, 25mg/100mg and 25mg/250 mg. For the 12 months ending June 30, 2009, Carbidopa and Levodopa tablets had U.S. sales of approximately $79 million for the same strengths, according to IMS Health. Mylan has launched this product.

Currently, Mylan has 123 ANDAs pending FDA approval representing $86.1 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $17.4 billion in annual brand sales, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
2. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
3. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
4. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
5. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
6. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
7. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
8. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
9. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
10. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
11. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... , ... Maury Regional Health has announced a large-scale adoption of AccuVein vein ... Maury Regional Medical Center is making vein visualization part of their standard of care. ... more importantly, helps our staff members locate a vein that will provide good access ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD ... ultimately, a cure. , The grants are awarded through a competitive application process ... a wide array of backgrounds and expertise in all areas relevant to PD research. ...
(Date:8/16/2017)... Sacramento, CA (PRWEB) , ... August 16, 2017 ... ... ($10.99, paperback, 9781498499613; $5.99, eBook, 9781498499620    ) shares that during the time of a ... as reminding Strawn of God's love, and all the many ways God shows ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... ... pain afflicting 8 of 10 Americans at some point in their lives, some of us ... equally vexing condition stems from a variety of causes that can be effectively targeted by ... president of Atlantic Spine Center. , Nestled between your neck and lower back, the ...
Breaking Medicine News(10 mins):